VintaBio provides comprehensive cell and gene therapy manufacturing services to pharmaceutical, biotechnology, academic, and government organisations that are developing drugs for use in clinical trials. With experienced staff dedicated to driving efficiency and producing high-quality cGMP-grade viral vectors, VintaBio addresses a vital and currently underserved area of cell and gene therapy development. Their current vector capabilities include, but are not limited to, adeno-associated virus (AAV) and lentiviral vectors (LVV).

Services include:
– Contract Manufacturing Organisation (CMO) services
– Cell and Gene Therapy production
– Plasmid production
– Viral Vector production
– Development of consistent, high-quality viral vectors

VintaBio continues to position itself as a key player in the biotechnology sector, committed to enhancing the development of gene therapies. For more information, please visit vintabio.com.